Abstract
There is increasing evidence that abnormalities in epigenetic mechanisms of gene expression contribute to the development of multiple sclerosis (MS). Advances in epigenetics have given rise to a new class of drugs, epigenetic drugs. Although many classes of epigenetic drugs are being investigated, at present most attention is being paid to two classes of epigenetic drugs: drugs that inhibit DNA methyltransferase (DNMTi) and drugs that inhibit histone deacetylase (HDACi). This paper discusses the potential use of epigenetic drugs in the treatment of MS, focusing on DNMTi and HDACi. Preclinical drug trials of DNMTi and HDACi for the treatment of MS are showing promising results. Epigenetic drugs could improve the clinical management of patients with MS.
Keywords: DNA methyltransferase inhibitor, epigenetic, histone deacetylase inhibitor, multiple sclerosis.
Graphical Abstract
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Cancer Drug Targets
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Current Drug Therapy
Related Books
Frontiers in Clinical Drug Research-Dementia
Anthocyanins: Pharmacology and Nutraceutical Importance
The Roles and Responsibilities of Clinical Pharmacists in Hospital Settings
Interventional Pain Surgery
Endoscopy and Fetoscopy Techniques for the Brain and Neuroaxis
Bioactive Compounds from Medicinal Plants for Cancer Therapy and Chemoprevention
Regenerative Medicine & Peripheral Nerve Endoscopy
Advances in Diagnostics and Immunotherapeutics for Neurodegenerative Diseases
Drug Addiction Mechanisms in the Brain
Software and Programming Tools in Pharmaceutical Research
77
2